What is the long-term trend for Charles River Laboratories's contract with customer, liability?

Over 3 years (2022 to 2025), Charles River Laboratories's contract with customer, liability has grown at a -4.1% compound annual growth rate (CAGR), from $290M to $256M.

Charles River Laboratories CRL Contract with Customer, Liability

Contract with Customer, Liability at other companies

DanaherDHR

——

Agilent TechnologiesA

——

BrukerBRKR

——

West Pharmaceutical ServicesWST

——

AbbottABT

——

FortiveFTV

——

Other financials

Income statement

See full

Revenue$995.8M+1.2%

Gross profit$349.0M-3.5%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Balance sheet

See full

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Cash flow

See full

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Valuation

See full

Market cap$8.91B+10.3%

Enterprise value$11.79B+8.5%

P/S2.2×+0.2×

Profitability

See full

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-4.6%—

FCF margin9.7%-4.3pp

Returns & leverage

See full

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Charles River Laboratories's contract with customer, liability?: Charles River Laboratories (CRL) reported contract with customer, liability of $256M in Q4 2025.
What is the long-term trend for Charles River Laboratories's contract with customer, liability?: Over 3 years (2022 to 2025), Charles River Laboratories's contract with customer, liability has grown at a -4.1% compound annual growth rate (CAGR), from $290M to $256M.